Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients

Current Opinion in Obstetrics and Gynecology

Volumn 18, Issue 1, 2006, Pages 24-28

  Kayl, Anne E ^a,b   Meyers, Christina A ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Chemotherapy; Ovarian cancer; Quality of life

Indexed keywords

AMIFOSTINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; PLATINUM DERIVATIVE; TRASTUZUMAB;

ALOPECIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COGNITIVE DEFECT; DISEASE SEVERITY; FATIGUE; FEMALE; HUMAN; MEDICAL DECISION MAKING; NAUSEA; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SOCIAL SUPPORT;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; OVARIAN NEOPLASMS; QUALITY OF LIFE;

EID: 33646479020     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gco.0000192996.20040.24     Document Type: Review

References (55)

1. Meyers CA, Abbruzzese JL. Cognitive functioning in cancer patients: effect of previous treatment. Neurology 1992; 42:434-436.
2. Ferguson RJ, Ahles TA. Low neuropsychologic performance among adult cancer survivors treated with chemotherapy. Curr Neurol Neurosci Rep 2003; 3:215-222.
3. Kornblith AB. Psychosocial adaptation of cancer survivors. In: Holland J, et al. editors. Textbook of psycho-oncology. New York: Oxford University Press; 1998. pp. 223-254.
4. Ahles TA, Saykin AJ, Furstenberg CT, et al. Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. J Clin Oncol 2005; 23:4399-4405. This paper discusses the impact of diagnosis and type of treatment on long-term survivors of breast cancer and lymphoma.
5. Herzog TJ. Recurrent ovarian cancer: how important is it to treat disease progression? Clin Cancer Res 2004; 10:7439-7449. An excellent review of various agents used in the management of ovarian cancer with discussions of toxicity and potential QOL effects. This paper also makes recommendations for areas of future investigation to address issues of treatment duration.
6. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519-2529. A good medical progress review with sections on epidemiology, familial syndromes, clinical presentation and the management of newly diagnosed and recurrent disease.
7. Pectasides D, Farmakis D, Koumarianou A. The role of neoadjuvant chemotherapy in the treatment of advanced ovarian cancer. Oncology 2005; 68:64-70. A good discussion of the potential benefits (reduced perioperative morbidity and improved QOL) of this alternative to standard treatment.
8. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: DeVita VT, Hellman S, Rosenberg RA, editors. Cancer: principles and practice of oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 1597-1632.
9. Ozols RF. Update on the management of ovarian cancer. Cancer J 2002; 2 (Suppl):S22-S30.
10. Gadducci A, Cosio S, Conte PF, Genazzani AR. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: A review of the literature. Crit Rev Oncol Hematol 2005; 55:153-166. A comprehensive review of treatment with summaries of research and discussions of toxicity.
11. Hahn CA, Jones EL, Blivin JL, et al. Prospective assessment of quality of life in ovarian cancer patients receiving whole abdomen hyperthermia and liposomal doxorubicin. Int J Hyperthermia 2005; 21:349-357.
12. Bezjak A, Tu D, Bacon M, et al. Quality of life in ovarian cancer patients: Comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. J Clin Oncol 2004; 22:4595-4603. A comparison of two treatments with QOL assessments completed prior to, during and after chemotherapy.
13. Le T, Hopkins M, Fung FK. Quality of life assessment during adjuvant and salvage chemotherapy for advance stage epithelial ovarian cancer. Gynecol Oncol 2005; 98:39-44. Evidence that disease response and treatment indication influence patient reported QOL.
14. Sood AK, Abu-Rustum NR, Barakat RR, et al. Fifth International Conference on Ovarian Cancer: Challenges and opportunities. Gynecol Oncol 2005; 97:916-923. Summary of presentations from the conference. Includes recent developments in ovarian cancer research as well as recommendations for future research.
15. Bodurka-Bevers D, Basen-Enquist K, Carmack CL, et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol 2000; 78:208-302.
16. Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2004; 13:219-227. Provides interesting insights from experienced cancer patients. Data obtained from semi-structured interviews reveals differences in preferred side-effect profiles for patients at different points in treatment and with different levels of social support.
17. Hilpert F, Stahle A, Tome O, et al. Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel- based chemotherapy - a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer 2005; 13: 797-805. Evaluation of this potential neuroprotective agent on treatment-related neuropathy.
18. Wolff AC. Systemic therapy. Curr Opin Oncol 1999; 11:468-474.
19. Green M, Hortobagyi GN. Neoadjuvant chemotherapy for operable breast disease. Oncology (Huntingt) 2002; 16:844-871.
20. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352:930-942.
21. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2346-2348. Comparison of treatment efficacy with QOL ratings.
22. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351:1451-1467.
23. Bottini A, Berruti A, Brizzi MP, et al. Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single institution phase III trial. Endocr Relat Cancer 2005; 12:383-392. This randomized study evaluated the benefits of combined chemo-hormonal therapy compared with chemotherapy alone in women with operable or locally advanced breast cancer.
24. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
25. Baselga J. Herceptin alone or in combination with chemotherapy in the treatment of HER-2 positive metastatic breast cancer: Pivotal trials. Oncology 2001; 61:14-21.
26. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as a first line treatment: The M77001 study group. J Clin Oncol 2005; 23:4265-4274. Data support the efficacy and safety of combination therapy with trastuzumab and a taxane for women with metastatic breast cancer.
27. Brezden CB, Phillips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18:2695-2701.
28. Schagen SB, van Dam FS, Muller MJ, et al. Cognitive deficits after post-operative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85: 640-650.
29. Tchen N, Juffs HG, Downie FP, et al. Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 2003; 21:4175-4183.
30. van Dam FSAM, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90: 210-218.
31. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 1995; 4:61-66.
32. Wefel JS, Lenzi R, Theriault RL, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer 2004; 100:2292-2299. Evidence of an association between cognitive dysfunction (attention, learning and processing speed impairments) and chemotherapy. Study incorporates pre-treatment cognitive assessments and a longitudinal design.
33. Avis NE, Crawford S, Manuel J. Psychosocial problems among younger women with breast cancer. Psycho-Oncology 2004; 13:295-308. Discusses prevalent concerns of younger women: premature menopause, sexual functioning and body image.
34. Avis NE, Crawford S, Manuel J. Quality of life among younger women with breast cancer. J Clin Oncol 2005; 23:3322-3330. Reports differential concerns faced by younger women diagnosed with breast cancer and risks for long-term reductions in QOL. Offers recommendations for patient education and social support.
35. Luoma M, Hakamies-Blomqvist L. The meaning of QOL in patients being treated for advanced breast cancer: a qualitative study. Psycho-Oncology 2004; 13:729-739. Utilized a semi-structured interview to obtain statements of personal meaning from breast cancer patients, with the emergence of three prevalent themes (control/autonomy, personal growth, hope).
36. Bottomley A, Therasse P, Piccart M, et al. Health-related quality of life in survivors of locally-advanced breast cancer: an international randomized controlled phase III trial. Lancet Oncol 2005; 6:287-294. Evidence that dose-intensive treatment has a temporary effect on patient reported QOL.
37. Conner-Spady BL, Cumming C, Nabholtz J-M, et al. A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation. Bone Marrow Transplant 2005; 36:251-259. Evidence for temporary declines in QOL following high-dose chemotherapy and implications for early psychosocial intervention.
38. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616-1634.
39. Petersdorf S, Upchurch C, Eyre H, et al. A phase II study of external beam radiation and chemotherapy with cisplatin/BCNU followed by BCNU alone for the treatment of incompletely resected high-grade brain tumors. Proc Annu Meet Am Soc Clin Oncol 1993; 12:A501.
40. Chamberlain MC. Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. Arch Neurol 1997; 54:554-558.
41. Castello MA, Clerico A, Deb G, et al. High-dose carboplatin in combination with etoposide (JET regimen) for childhood brain tumors. Am J Pediatr Hematol Oncol 1990; 12:297-300.
42. Brown WE, Marsh J, Wolcott D, et al. Cognitive function, mood and P3 latency: effects of the amelioration of anemia in dialysis patients. Neuropsychologia 1991; 29:35-45.
43. Marsh J, Brown WE, Wolcott D, et al. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 1991; 39:155-163.
44. Temple RM, Deary IJ, Winney RJ. Recombinant erythropoietin improves cognitive function in patients maintained on chronic ambulatory peritoneal dialysis. Nephrol Dial Transplant 1995; 10:1733-1738.
45. Littlewood TJ, Bajetta E, Nrtier JWR, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002; 19:2865-2874.
46. Straus DJ. Epoetin alfa as a supportive measure in hematologic malignancies. Semin Hematol 2002; 39 (Suppl 3):25-31.
47. Hudis C, Vogel C, Gralow JR, Williams D. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life. Clin Breast Cancer 2005; 6:132-142. In this prospective study, the use of epoetin alfa for the treatment of mild anemia was associated with improved QOL. This paper offers guidelines for treatment with recommendations for additional study.
48. Iop A, Manfredi AM, Bonura S. Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Ann Oncol 2004; 15:712-720.
49. Tierney A, Leonard R, Taylor J, et al. Side effects expected and experienced by women receiving chemotherapy for breast cancer. BMJ 1991; 302:272.
50. Respini D, Jacobsen PB, Thors C, et al. The prevalence and correlates of fatigue in older cancer patients. Crit Rev Oncol Hematol 2003; 47:273-279.
51. Lesage P, Portenoy RK. Management of fatigue in the cancer patient. Oncology 2002; 16:373-378.
52. Valentine AD, Passik SD, Massie MJ. Psychiatric and psychosocial issues. In: Levin VA, editor. Cancer in the nervous system. 2nd ed. New York: Oxford University Press; 2002. pp. 572-589.
53. Tarbuck AF, Paykel ES. Effects of major depression on the cognitive function of younger and older patients. Psychol Med 1995; 25:285-296.
54. Christensen H, Griffiths K, MacKinnon A, Jacomb P. A quantitative review of cognitive deficits in depression and Alzheimer-type dementia. J Intern Neuropsychol Soc 1997; 3:631-651.
55. Lee BN, Dantzer R, Langley KE, et al. A cytokine-based neuroimmunological mechanism of cancer-related symptoms. Neuroimmunomodulation 2004; 11:279-292.